MD Anderson Cancer Center and Nanobiotix announce a large-scale, comprehensive clinical collaboration on NBTXR3
Collaboration will initially support nine new phase I/II clinical trials with Nanobiotix's first-in-class agent NBTXR3 for use in treating six ...